At the news
? BEARISHIMPACT 6/10 S-3 filed Mar 23, 2026 at 17:23 ET
Sutro Biopharma has filed an S-3 shelf registration allowing it to raise up to $300 million in various securities, including a $100 million at-the-market (ATM) offering of common stock through TD Cowen. This signals a need for capital, likely due to its cash burn and recent restructuring. The offering will be dilutive to existing shareholders, with proceeds used for general corporate purposes.
- S-3 shelf registration filed for up to $300 million in securities (common stock, preferred stock, debt, warrants, etc.).
- Specific $100 million ATM offering of common stock through TD Cowen is part of the shelf registration.
- Company's market cap is $340 million, meaning the $100 million offering represents a 29.4% potential dilution of market cap.
- Company reported a net loss of $144.3 million for the nine months ended September 30, 2025, indicating significant cash burn.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access